Medication resistance & in-vitro trials

Professional audience only

This page only introduces research background.

Concrete experimental methods are not public; detailed operating materials go only to professional partners who pass credential checks.

Patients, families, and the general public should not self-experiment from this page.

Any research must be designed by a professional team and pass ethics review.

I. Two phenomena that still need research

Treatment resistance

Treatment resistance means that after adequate-dose, adequate-duration standard treatment, the patient still does not get a sufficient response.

Drug tolerance

Drug tolerance means a drug works at first, but effect gradually weakens with continued use.

Misdiagnosis, missed doses, insufficient course, individual metabolism, drug interactions, receptor adaptation, and disease change may all take part.

These common causes should first be ruled out by professionals.

Spirit Medicine’s judgment is: after excluding the common factors above, some treatment resistance and drug tolerance still come from the behavior and operations of a possessing unclean spirit.

The same set of spirit factors may also temporarily enhance drug effect in the opposite direction.

What behaviors, how they operate, and how to verify are not disclosed on the public page.

II. Treatment resistance is not rare

Depression

Treatment-resistant depression usually means insufficient response after at least two adequate-dose, adequate-duration antidepressant courses.

A 2023 World Psychiatry review notes that among patients with major depression receiving high-quality treatment, at least about 30% meet treatment-resistant depression criteria.

Definitions differ across studies, so numbers vary widely.

Schizophrenia

Public research often estimates treatment-resistant schizophrenia at 20%–30%.

A 2023 meta-analysis of 50 studies and 29,390 people yielded an overall estimate of 36.7%; when only lower-bias-risk studies were included, the estimate was 28.4%.

Other psychiatric disorders

In bipolar disorder, anxiety, PTSD, and OCD, long-term nonresponse, partial response, and repeated treatment failure also exist.

Definitions are not unified across diseases; one fixed number should not summarize them.

Drug tolerance likewise exists across many CNS drug classes.

It may involve receptor adaptation, neural compensation, metabolic change, and other factors.

III. Reduced and enhanced drug effect from a possessing unclean spirit

Spirit Medicine states clearly:

They may appear quickly, and need not accompany change in standard prescription dose.

Under this frame, treatment resistance and drug tolerance are treated as different time expressions of the same class of spirit factor.

This is a research judgment, not a peer-reviewed medical settled conclusion.

Concrete conditions, methods, and operating details are not public.

IV. Why it may matter

If these signals cannot be repeated, or can be explained by adherence, expectancy, natural course, and ordinary pharmacological factors, no new theory is needed.

This research does not deny the roles of neurotransmitters, receptors, hepatic/renal metabolism, the autonomic system, and drug concentration.

It proposes: beyond these layers, the possessing unclean spirit’s behaviors and operations also change drug effect.

Whatever later results, this must not be used to encourage stopping medication, taking less medication, or denying existing psychiatric treatment.

V. Directions for professional collaboration

The first collaboration stage is not immediate patient experiments, but:

• professionals review existing records;
• judge whether the phenomena deserve formal research;
• jointly set safety boundaries and ethics conditions;
• then decide whether to design a verification plan.

Concrete materials go only to partners who pass identity checks, hold professional credentials, and agree to confidentiality and ethics boundaries.